Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Assets Average (2016 - 2025)

Amicus Therapeutics filings provide 15 years of Assets Average readings, the most recent being $909.3 million for Q4 2025.

  • On a quarterly basis, Assets Average rose 15.72% to $909.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $909.3 million, a 15.72% increase, with the full-year FY2025 number at $867.5 million, up 11.0% from a year prior.
  • Assets Average hit $909.3 million in Q4 2025 for Amicus Therapeutics, up from $842.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $930.9 million in Q4 2021 to a low of $712.3 million in Q1 2023.
  • Median Assets Average over the past 5 years was $786.6 million (2024), compared with a mean of $798.9 million.
  • Biggest five-year swings in Assets Average: fell 20.31% in 2022 and later increased 15.72% in 2025.
  • Amicus Therapeutics' Assets Average stood at $930.9 million in 2021, then fell by 20.31% to $741.8 million in 2022, then grew by 3.93% to $771.0 million in 2023, then increased by 1.92% to $785.8 million in 2024, then rose by 15.72% to $909.3 million in 2025.
  • The last three reported values for Assets Average were $909.3 million (Q4 2025), $842.1 million (Q3 2025), and $802.6 million (Q2 2025) per Business Quant data.